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Objective: Paraparesis and paraplegia after thoracic endovascular aneurysm repair (TEVAR) is a greatly feared compli-
cation. Multiple case series report this risk up to 13% with no, or inconsistent, application of interventions to enhance and
protect spinal cord perfusion. In this study, we report our single-institution experience of TEVAR, using the same
proactive spinal cord ischemia protection protocol we use for open repair.
Methods: Endovascular thoracic aortic interventions were performed for both on-label (aneurysm) and off-label (trauma,
other) indications. Aortic area covered was recorded as a fraction from the subclavian to celiac origins and reported as
a percentage. If debranching was required, measurements were taken from the most distal arch vessel left intact. Intra-
operative imaging and postoperative computed tomographic angiogram were used in calculating aortic percent coverage.
Outcomes were recorded in a clinical database and analyzed retrospectively. The spinal cord ischemia protection included
routine spinal drainage (spinal ﬂuid pressure <10 mm Hg), endorphin receptor blockade (naloxone infusion), moderate
intraoperative hypothermia (<35C), hypotension avoidance (mean arterial pressure >90 mmHg), and optimizing cardiac
function.
Results: From 2005 to 2012, 94 consecutive TEVARs were studied. Indications were thoracic aneurysm (n[ 48), plaque
rupture with or without dissection (n[ 23), trauma (n[ 15), and other (n[ 8). Forty-nine percent were acute, average
age was 68.5 years, 60% (n[ 56) were male, and the mean follow-up was 12 months. Mean length of aortic coverage was
161 mm, correlating to 59.4% aortic coverage. One patient had delayed paralysis (1.1%; observed/expected ratio, 0.12)
and recovered enough to ambulate easily without assistance. Other complications included wound (7.5%), stroke (4.3%),
myocardial infarct (4.3%), and renal failure (1.1%).
Conclusions: Proactive spinal cord protective protocols appear to reduce the incidence of spinal ischemia after TEVAR
compared with historical series. This study would suggest that active, as opposed to reactive, approaches to spinal
ischemia portend a better long-term outcome. Multimodal protection is essential, especially if long segment coverage is
planned. (J Vasc Surg 2013;57:1537-42.)Over the last 3 decades, great progress has occurred in
reducing the incidence of spinal cord ischemia and paralysis
after open thoracic aortic aneurysm repair.1,2 From the
initial observation of the artery of Adamkiewicz nearly
150 years ago, to its implication in neurologic complica-
tions after aortic surgery over the past 50 years,3 to
a more complex understanding of the collateral network
concept,4 the rate of paraplegia after thoracic aortic surgery
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augment spinal perfusion are essential in reducing the inci-
dence of this disabling complication.1,2,5-11 Furthermore,
consistent and uniform application of these protocols is
essential, as demonstrated by Hollier et al, where spinal
ischemia was reduced from 6% to 0% over an 11-year
period with the implementation of a proactive protocol.12
As the application of endovascular aneurysm repair has
progressed to include thoracic pathologies, these theories
again need to be revisited. Over the last decade, it has
become increasingly apparent that thoracic endovascular
aneurysm repair (TEVAR) carries the same risk of parapa-
resis/paraplegia as open thoracic aortic repair.13-17
A recent review by Rizvi and Sullivan estimated the overall
risk of paraplegia/paraparesis after TEVAR to be 3.9%.
This was based on a meta-analysis of 5349 patients in
over 50 published reports. More importantly, the rate of
paraplegia ranged from 0% to 13.3% among the reported
case series, each with variable spinal cord protection proto-
cols and inconsistent implementation.16
It is clear that with inconsistent application of interven-
tions to enhance and protect spinal cord perfusion, para-
plegia rates can be unnecessarily and unacceptably
high.12,16 We have previously shown that aggressive spinal1537
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with an acceptable risk proﬁle.18 The goals of any effective
spinal protection protocol include increasing the spinal
perfusion pressure, buffering the ischemia-reperfusion
injury, and reducing the spinal cord metabolic demand.
Speciﬁc interventions, either chemical or mechanical,
addressing each of these fundamental points synergistically
increase perfusion while reducing the ischemia/reperfusion
response, neuronal metabolic activity, and excitotoxicity.
In this study, we report our single-institution experience
of TEVAR, using the same proactive spinal cord ischemia
protection protocol we use for open aneurysm repair. This
protocol consists of uniform spinal ﬂuid drainage, permissive
mild hypothermia, increasing mean arterial blood pressure,
and multimodal pharmico-prophylaxis.
METHODS
During a 7-year contiguous period from January 1,
2005 to January 31, 2012, all TEVARs were prospectively
enrolled into our institutional clinical database. Demo-
graphic data, clinical comorbidities, and outcomes data
were recorded. In addition, postoperative complications
including endoleak, wound-related complications, stroke,
myocardial infarction, renal failure, paraplegia/paraparesis,
and death were also monitored and recorded.
All patients receiving a Food and Drug Administration-
approved thoracic endovascular device were included in
analysis, regardless of on- or off-label indication for implan-
tation. Both elective and emergent presentations were
included in this cohort, as well as patients requiring either
abdominal or cervical arch debranching procedures to
ensure proper landing zone. Trauma patients with short
segment coverage using extension cuff segments were
excluded from this study.
In standard TEVAR implantations, those patients not
requiring a debranching procedure, aortic length covered
was recorded, in centimeters, as a fraction from the left
subclavian to celiac origins. Measurements were taken
utilizing the intraoperative imaging and ﬁrst postoperative
computed tomographic angiogram scan. If either abdom-
inal or arch debranching procedures were required to
assure adequate landing zone, measurements were taken
from the most distal arch vessel left intact to the most prox-
imal abdominal branch vessel left intact. Because of the
confounding issue of differing absolute aortic lengths
among patients, the length of aortic coverage was normal-
ized by calculating a percent aortic coverage. These calcu-
lations were completed retrospectively. Total aortic graft
coverage length was divided by the total aortic length,
allowing for better comparison of normalized percent aorta
covered among patients with variable absolute lengths
covered.
The spinal cord ischemia protection protocol included
routine spinal drainage in all patients. Spinal drains were
placed in all patients, regardless of elective or emergent
presentation, so long as hemodynamic stability allowed.
In the setting of unstable rupture, operative intervention
without spinal drainage can be undertaken, but we striveto obtain spinal drainage in all patients. All patients in
this cohort received spinal drains, which were placed in
the operating room by our dedicated cardiovascular anes-
thesiology group. Goals of drainage were to a spinal ﬂuid
pressure 8 mmHg intraoperatively and 10 mm Hg postop-
eratively. This was accomplished by draining in 5 to 15 mL
aliquots utilizing a buretrol system until the target pressure
was achieved. All drainage was accomplished by gravity
alone. There was no volume limit threshold at which spinal
ﬂuid drainage was ceased, although average intraoperative
volumes ranged from 100 to 130 mL. If bloody ﬂuid
drainage was noted, the spinal drain was clamped, and
a stat noncontrast head computed tomography was ob-
tained to evaluate for extra-axial hemorrhage. In uncompli-
cated cases, spinal ﬂuid drainage was stopped and the spinal
drain clamped once brisk lower extremity leg lifting was
reproducibly present on physical examination. Spinal drains
were routinely removed 24 to 48 hours after surgery.
All patients received methylprednisolone 30 mg/kg
after anesthetic induction, up to a maximum dose of 2 g.
Patients also received mannitol, 12.5 g shortly after anes-
thesia induction. Mannitol has been shown to reduce cere-
brospinal ﬂuid pressures experimentally and clinically.
Experimentally, mannitol has also been shown to function
as a free-radical scavenger and serve as an osmotic diuretic
with renal protective properties.19
Moderate intraoperative hypothermia was allowed
through radiative loss and the administration of cold intra-
venous ﬂuids, to a goal temperature of less than 35C, but
more than 32C. Postoperatively, active rewarming
(thermal warming blankets) was strictly avoided, only
ambient rewarming was allowed. Active rewarming blan-
kets were avoided because of the potential induction of
peripheral vasodilation. This can result in shunting of blood
away from central structures, including the spinal cord.
Reduced blood ﬂow coupled with increased temperature
and metabolic demands are major contributors to spinal
ischemia risk. During both the intraoperative and postoper-
ative time frames, mean arterial blood pressures were kept
>85 mm Hg. In addition, patients were maintained on
a continuous naloxone infusion starting before anesthesia
induction and lasting for 24 hours postoperatively.
Naloxone infusion was prepared with 2.5 mg in 250 mL
diluent (10 mcg/mL) and infused at 1 mcg/kg/h.
RESULTS
From 2005 to 2012, 94 consecutive TEVAR implanta-
tions were studied. All procedures were performed at
a single institution. Indications for repair included degener-
ative thoracic aneurysm (n ¼ 48), plaque rupture/intramu-
ral hematoma (n ¼ 23), trauma (n ¼ 15), and other
(n ¼ 8). The other group included acute type B dissection
(n ¼ 3), pseudoaneurysm (n ¼ 4), and one patient with
presumed aortoesophageal bleeding. There were no
patients with known connective tissue disorders included
in this study cohort. The mean aortic diameter at the
time of intervention for those patients with a degenerative
aneurysm was 6.5 cm (minimum, 5.6 cm; maximum,
Table I. Patient characteristics
Category Value (%)
Age, years 54 6 15
Sex
Male 56 (60)
Female 38 (40)
Presentation
Elective 48 (51)
Emergent 46 (49)
Indication
Thoracic aneurysm 48 (51)
Plaque rupture/hematoma 23 (24)
Trauma 15 (16)
Other 8 (9)
Procedure
Standard TEVAR 77 (82)
TEVAR þ arch debranching 15 (16)
TEVAR þ abdominal debranching 2 (2)
Comorbidities
None 14 (15)
Coronary artery disease 30 (32)
Chronic obstructive pulmonary disease 20 (21)
Diabetes 2 (2)
Hypertension 75 (80)
ASA score
ASA 1 0 (0)
ASA 2 4 (4)
ASA 3 36 (38)
ASA 4 46 (49)
ASA 5 8 (8)
ASA 6 0 (0)
ASA, American Society of Anesthesiologists; TEVAR, thoracic endovascular
aneurysm repair.
Summary data of patient demographics, acuity of presentation, indication
for operation, and comorbid conditions in all 94 TEVAR patients.
Table II. Patient data and outcomes
Category Value (%)
Mean aortic length coverage, mm 161 6 73
Mean aortic coverage, % 59.4 6 19
Complications
Endoleak 10 (10.6)
Wound breakdown/infection 7 (7.4)
Stroke 4 (4.3)
Myocardial infarct 4 (4.3)
Acute renal failure 1 (1.1)
Paraplegia 1 (1.1)
Death 7 (7.4)
TEVAR, Thoracic endovascular aneurysm repair.
Summary of mean aortic distance (mm) and percent aortic coverage along
with postoperative outcomes data in all 94 TEVAR patients.
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ulcerated plaque or intramural hematoma with symptoms,
including back or chest pain. All trauma patients with
evidence of intimal disruption, intramural hematoma, or
extravasation were considered for TEVAR. Indication for
TEVAR in acute type B dissection included renovisceral
or limb malperfusion.
The mean follow-up time period was just over
12 months. Debranching procedures were required in
17 cases (18.1%); of these, 15 were arch debranchings
and two abdominal debranchings. Any patient requiring
extension of the proximal landing zone underwent
debranching at the time of TEVAR, or in a staged proce-
dure prior to TEVAR. All patients underwent prophylactic
debranching preceding TEVAR. There were 14 subclavian
transposition/bypass procedures completed. One patient
underwent both left subclavian and left common carotid
revascularization in preparation for TEVAR. Both abdom-
inal debranching procedures consisted of four-vessel revas-
cularization: celiac/hepatic, superior mesenteric artery, and
both renal arteries.
Comorbidities of the group are listed in Table I. The
mean length of aortic coverage was 161 mm, and the
average normalized aortic percent coverage was 59.4% of
total aortic length. There were 10 endoleaks identiﬁed
during the course of the study. Seven of these were either
type Ia or Ib leaks; these were all treated with proximal or
distal extension. There was one type III leak treated with
a bridging device, and two type II leaks with no sac expan-
sion that ultimately thrombosed on their own. There were
no cases of paraplegia or paralysis related to the repeat
interventions. There was one patient who developed
a cold leg after percutaneous closure device failure resulted
in common femoral artery occlusion. This was removed
operatively with no long-term adverse sequaelae. In addi-
tion, seven (7.4%) patients developed wound breakdown
or superﬁcial wound infections. There were four patients
each who suffered perioperative myocardial infarction or
cerebrovascular accident (Table II).
There was one delayed paralysis (1.1%; observed/
expected ratio, 0.12). This patient had undergone elective
TEVAR covering the proximal 63% of the native aorta
along with arch debranching with a subclavian transposi-
tion for aneurysmal disease, patient number 37 (Fig).
The paraplegia was associated with a period of postopera-
tive hypotension. It responded to aggressive blood pressure
augmentation and ﬂuid resuscitation. The patient was able
to recover and ambulate easily without assistive devices at
the time of discharge. During the course of the study, there
were no other patients that presented with delayed
paraplegia.
There were seven deaths during the course of this
study. The mean time to death after TEVAR in these
patients was 1.1 years (range, 0.72-1.86 years). Six of these
were after hospital discharge and >30 days from the index
case. There was one intraoperative death in this cohort.
This was an 87-year-old female who presented with an
acute plaque rupture and extensive intramural hematoma.Upon device deployment, the patient became precipitously
hypotensive. Repeat angiogram showed proximal conver-
sion to free rupture into the left chest. A second device
was brought on the ﬁeld to deploy more proximally, but
the patient ultimately expired in the operating room.
There was one complication related to spinal drain
placement in this patient group. This patient developed
an epidural hematoma with cord compression after he
was started on low-molecular-weight heparin. He had
Fig. Percent aortic coverage. Each of the 94 patients in this study is represented by a single bar in this ﬁgure and
numbered 1 to 94 accordingly. Patients are presented sorted by coverage extent and not chronological order for ease of
interpretation. The open white bars represent proximal and/or distal uncovered aortic segments, measured as a percent
of total aortic length. The blue shaded bar represents the percent of aorta covered with the thoracic endovascular
aneurysm repair (TEVAR) devices. Patients requiring debranching procedures are noted by the blue (arch debranching)
and purple (abdominal debranching) highlighted circles overlying the patient numbers. The solitary paraplegia patient,
number 37, is also denoted with a red highlighted circle.
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room on postoperative day 6 with low back pain and bilat-
eral lower extremity pain and weakness. Imaging revealed
the epidural hematoma, and urgent decompressive lami-
nectomy was completed. He regained function and recov-
ered uneventfully.
DISCUSSION
In this study, we have examined the outcomes related
to paraplegia and paraparesis after TEVAR with an aggres-
sive and proactive spinal cord protection protocol. We
observed an overall paraplegia event rate of 1.1%, much
lower than other reported case series. In addition, this
rate is lower than those results of the major multicenter
international registry papers (European Collaborators on
Stent Graft Techniques for Thoracic Aortic Aneurysm
and Dissection Repair [EUROSTAR], 4.0%; GORE TAGthoracic endoprosthesis registry [GORE-TAG], 3%; Talent
Thoracic Retrospective Registry [TTR], 1.7%; Valiant
Thoracic Stent Graft System Clinical Study [VALOR II],
2.5%).20-23 A recent meta-analysis review of published
studies related to spinal protection showed an overall rate
of paraplegia/paraparesis of 3.88%. Among those groups
that employed routine spinal ﬂuid drainage (SFD), this
rate was 3.2%. Among those that never used SFD, the
rate was 3.47%, and lastly, among those who selectively
practiced SFD, the rate was 5.6%.24 Although our study
is limited by the relatively low number of patients and
heterogeneous pathologies, we believe it illustrates an
essential concept about spinal cord perfusion and protec-
tion. Spinal cord perfusion during and after thoracic aortic
surgery, including TEVAR, is maintained by a complex
interplay between perfusion pressure, collateral networks,
and the ischemia-reperfusion response. The ultimate goal
JOURNAL OF VASCULAR SURGERY
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plegia/paraparesis using proactive measures and not rescue
after it has already ensued. The consequences of failure to
rescue are too great given the relatively simple and low-
risk prophylactic measures that can be implemented.
In humans, the artery of Adamkiewicz has variable
origin and is presumed to give rise to the greater radicular
artery, a major feeder to the anterior spinal artery and
perfusion source for the ventral motor columns.3 In addi-
tion, spinal cord blood ﬂow is a plexus circulation with
collateral feed from other intercostal radicular arteries,
subclavian, vertebral, hypogastric, and other collateral
contributors.25-27 When these collateral networks become
compromised, or sacriﬁced, because of aortic surgery,
spinal perfusion can suffer, and paraplegia may result.4
Certain patients are at increased risk for disruption of the
plexus network. Those who have had prior aortic surgery,
those with hypogastric or left subclavian stenosis/occlu-
sion, and those with occluded lumbar arteries are at
increased risk because of reduced inputs. In addition, those
patients who require a long segment of thoracic coverage
are at higher risk because of increased blood ﬂow disrup-
tion. The more open intercostal arteries covered during
TEVAR, the higher the risk of resulting paraplegia/parapa-
resis. It is because of the complex interplay of all these vari-
ables that spinal protection must be undertaken, especially
in high-risk patients. Unfortunately, no single variable, or
group of characteristics, can completely predict which
patients will develop paraplegia/paraparesis post-TEVAR.
Because of this, and the low morbidity associated with
the interventions we utilize, we support the routine use
of this proactive multimodal spinal protection in all patients
undergoing formal TEVAR.
The goals of spinal cord perfusion protection during
thoracic aortic intervention are threefold: prolong spinal
cord ischemic tolerance, reduce the ischemia reperfusion
response, and improve spinal cord oxygen delivery.
Improved ischemic tolerance can be accomplished with
mild intraoperative hypothermia. We typically cool to
34C. This helps to reduce spinal cord metabolic activity
and spinal cord oxygen requirements. Ischemia-reperfusion
injury can be attenuated with the routine use of induction
steroid bolus to stabilize cellular membranes and minimize
local inﬂammatory response pathways.28 In addition,
naloxone infuse has been shown to reduce the release of
excitatory neurotransmitters from ischemic neurons.29
Finally, mannitol acts as a free-radical scavenger, helping to
blunt the reperfusion injury response.19
The third factor, spinal cord oxygen delivery, is the
summation of hemodynamic and oxygen content factors.
Blood ﬂow is perhaps best visualized by the equation
spinal cord perfusion pressure equals mean arterial blood
pressure minus spinal ﬂuid pressure. With this relation-
ship, it is clear that augmentation of cardiac function
and reduction in spinal ﬂuid pressure are key to preserving
spinal perfusion. We routinely employ spinal ﬂuid
drainage to augment microvascular perfusion. We choose
an intraoperative drainage threshold of 8 mm Hg anda postoperative threshold of 10 mm Hg. This is in part
because of our observations with open thoracic aortic
surgery. We have noted a higher incidence of para-
plegia/paraparesis in those patients with spinal ﬂuid pres-
sures over 10 mm Hg. Two recent studies have conﬁrmed
the observation that more aggressive spinal ﬂuid drainage
improves paraplegia/paraparesis rescue.30,31 The risks of
spinal ﬂuid drainage are low, and we believe are offset
by the beneﬁts derived from paraplegia prevention.18
We recommend holding prophylactic heparin dosing the
morning of spinal drain removal and for the next 6 to 8
hours after drain removal. Obviously, adequate hemo-
globin and oxygen are necessary to provide adequate
tissue oxygen delivery, and avoidance of hypotension,
hypoxemia, and anemia during and after intervention is
essential. Oxygen delivery is directly dependent upon
oxygen content, and we routinely strive for hemoglobin
concentrations $10 g/dL. The use of active warming
blankets can cause peripheral vasodilation, resulting in
diversion of blood ﬂow from central structures, including
the spinal cord. For this reason, we advocate passive
rewarming, which has the added beneﬁt of maintaining
reduced neuronal metabolic demands during this critical
perioperative phase. When patients present with delayed
paraplegia, we advocate the routine use of spinal ﬂuid
drainage and pharmacologic elevation of blood pressure
to a mean pressure of 85 mm Hg or greater. Although
endovascular thoracic aortic repair clearly provides an
overall reduction in much of the morbidity associated
with open thoracic aortic repair, paraplegia does not
appear to be signiﬁcantly reduced. TEVAR presents
a unique insult to the spinal plexus network, with abrupt,
oftentimes, long-segment input disruption and the added
risk of embolization from lateral displacement of lining
thrombus. In addition, this often occurs at relatively
normothermic body temperatures, further amplifying
the resulting ischemic injury. Because of this, we advocate
a consistent approach to the prevention of paralysis/para-
paresis during TEVAR based on the pathophysiology of
spinal cord ischemia. We utilize the same multimodal
protocol that is used during our open thoracic aneurysm
repairs. Careful attention to cardiac function, perfusion
pressure, spinal ﬂuid pressure, along with chemo-
prophylaxis has reduced the incidence of spinal ischemia
in our hands to roughly 1%, regardless of elective or
emergent presentation.
CONCLUSIONS
Proactive spinal cord protective protocols appear to
reduce the incidence of spinal ischemia after TEVAR
when compared to historical series. This study would
suggest that active, as opposed to reactive, approaches to
spinal ischemia portend a better long-term outcome. The
ultimate goal of spinal cord protection must be the preven-
tion of paraplegia/paraparesis using proactive measures
and not rescue after it has already occurred. The conse-
quences of failure to rescue are too great given the rela-
tively simple and low-risk prophylactic measures that can
JOURNAL OF VASCULAR SURGERY
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essential, especially if long-segment coverage is planned.
These strategies should include speciﬁc interventions
directed toward improving spinal cord ischemic tolerance,
reducing the ischemia reperfusion response, and improving
spinal cord oxygen delivery.
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